Hospitals launch chatbots, creating another funnel for patient intake
Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the…
Insurers, hospitals agree AI scribes raise medical bills. What now?
To hear health systems tell the story, artificial intelligence tools like ambient scribes are helping not only reduce…
GOP Sen. Johnson investigating FDA rare disease drug rejections
WASHINGTON — Sen. Ron Johnson (R-Wis.) said he is investigating the Food and Drug Administration’s rejections of rare disease…
How Hims has transformed medicine in a few short years
As the Super Bowl approached halftime, Hims & Hers publicly staked its claim to preventive medicine in front…
Why clinical trials on nutritional supplements are hard to design
Walk into any drugstore, natural market, or Costco and you’ll find a dazzling array of supplements promising everything…
Study on timing cancer treatments to the morning comes under fire
Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT…
FDA’s Høeg plans to scrutinize SSRIs, RSV shots for babies
WASHINGTON — Tracy Beth Høeg, the top drug regulator at the Food and Drug Administration, indicated in her…
We’re reading about China’s GLP-1 drugs, a puzzling FDA rejection
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and rewarding…
Consumer group presses U.S. to authorize generic GLP-1s
Public Citizen petitioned the Trump administration to use a federal law to authorize generic competitors for GLP-1 drugs…
Hims & Hers compounder received FDA warning letter| STAT
The Food and Drug Administration late last year issued a warning letter to MedisourceRx, a compounding pharmacy owned…